Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
GODREJAGRONSE
AVANTIFEEDNSE
MUKKA-BENSE
KSENSE
AJOONINSE
Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 19% | 7% | 44% |
| - | 42% | 6% | 19% |
| - | - | - | 0% |
| 25% | 24% | 17% | 12% |
Peer Comparison
Symbol
GODREJAGRO
AVANTIFEED
MUKKA-BE
KSE
AJOONI
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 578.6 | ₹11177 Cr | 23.81 | 5.99 | 36.26 | ₹473 Cr |
| 705 | ₹9723 Cr | 21.76 | 5.06 | 37.19 | ₹606 Cr |
| 25 | ₹746 Cr | 9.41 | 0.53 | 3.29 | ₹52 Cr |
| 168.15 | ₹545 Cr | 44.21 | -0.38 | 6.36 | ₹84 Cr |
| 2.97 | ₹55 Cr | 12.91 | 0.03 | 0.42 | ₹4 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹509 Cr | ₹490 Cr | ₹381 Cr | ₹653 Cr | ₹245 Cr | ₹171 Cr | ₹382 Cr | ₹303 Cr | ₹149 Cr | ₹172 Cr | ₹257 Cr | ₹517 Cr | ₹332 Cr | ₹274 Cr | ₹421 Cr | ₹397 Cr |
| ₹9 Cr | ₹2 Cr | ₹15 Cr | ₹5 Cr | ₹6 Cr | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹6 Cr | ₹4 Cr | ₹3 Cr | -₹18 L | ₹2 Cr |
| ₹518 Cr | ₹491 Cr | ₹396 Cr | ₹658 Cr | ₹251 Cr | ₹173 Cr | ₹386 Cr | ₹309 Cr | ₹152 Cr | ₹175 Cr | ₹260 Cr | ₹523 Cr | ₹336 Cr | ₹277 Cr | ₹421 Cr | ₹399 Cr |
| ₹472 Cr | ₹446 Cr | ₹352 Cr | ₹612 Cr | ₹228 Cr | ₹159 Cr | ₹355 Cr | ₹266 Cr | ₹143 Cr | ₹161 Cr | ₹228 Cr | ₹501 Cr | ₹297 Cr | ₹261 Cr | ₹379 Cr | ₹365 Cr |
| ₹51 Cr | ₹50 Cr | ₹49 Cr | ₹50 Cr | ₹27 Cr | ₹17 Cr | ₹33 Cr | ₹47 Cr | ₹13 Cr | ₹17 Cr | ₹35 Cr | ₹25 Cr | ₹42 Cr | ₹19 Cr | ₹44 Cr | ₹37 Cr |
| ₹17 Cr | ₹16 Cr | ₹15 Cr | ₹15 Cr | ₹13 Cr | ₹11 Cr | ₹10 Cr | ₹11 Cr | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹4 Cr |
| ₹29 Cr | ₹28 Cr | ₹29 Cr | ₹32 Cr | ₹10 Cr | ₹3 Cr | ₹20 Cr | ₹32 Cr | ₹23 L | ₹6 Cr | ₹26 Cr | ₹16 Cr | ₹33 Cr | ₹10 Cr | ₹35 Cr | ₹30 Cr |
| ₹19 Cr | ₹20 Cr | ₹21 Cr | ₹24 Cr | ₹7 Cr | ₹2 Cr | ₹14 Cr | ₹26 Cr | ₹65 L | ₹5 Cr | ₹28 Cr | ₹10 Cr | ₹27 Cr | ₹6 Cr | ₹24 Cr | ₹25 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — |
| ₹30 Cr | ₹30 Cr | ₹30 Cr | ₹22 Cr | ₹22 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr |
| ₹469 Cr | ₹411 Cr | ₹366 Cr | ₹126 Cr | ₹76 Cr | ₹61 Cr | ₹51 Cr | ₹38 Cr |
| ₹469 Cr | ₹411 Cr | ₹366 Cr | ₹126 Cr | ₹76 Cr | ₹61 Cr | ₹51 Cr | ₹38 Cr |
| ₹499 Cr | ₹441 Cr | ₹396 Cr | ₹148 Cr | ₹98 Cr | ₹67 Cr | ₹57 Cr | ₹44 Cr |
| ₹30 Cr | ₹16 Cr | ₹12 Cr | ₹8 Cr | ₹5 Cr | ₹3 Cr | ₹1 Cr | ₹11 L |
| ₹25 Cr | ₹2 Cr | ₹6 Cr | ₹5 Cr | ₹7 Cr | ₹6 Cr | ₹7 Cr | ₹35 L |
| ₹7 Cr | ₹18 L | ₹18 L | ₹0 | ₹2 Cr | ₹3 Cr | ₹7 Cr | ₹16 Cr |
| -₹37 L | ₹3 Cr | ₹2 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr |
| ₹9 Cr | ₹2 Cr | ₹82 L | ₹6 Cr | ₹2 Cr | ₹54 L | ₹82 L | ₹44 L |
| ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹40 L | ₹1 Cr | ₹16 L |
| ₹43 Cr | ₹9 Cr | ₹12 Cr | ₹17 Cr | ₹15 Cr | ₹13 Cr | ₹18 Cr | ₹20 Cr |
| — | — | — | — | — | — | — | — |
| ₹241 Cr | ₹142 Cr | ₹136 Cr | ₹131 Cr | ₹98 Cr | ₹100 Cr | ₹81 Cr | ₹60 Cr |
| ₹65 Cr | ₹13 Cr | ₹30 Cr | ₹10 Cr | ₹10 Cr | ₹22 Cr | ₹7 Cr | ₹8 Cr |
| ₹720 Cr | ₹443 Cr | ₹352 Cr | ₹247 Cr | ₹158 Cr | ₹146 Cr | ₹124 Cr | ₹66 Cr |
| ₹23 Cr | ₹13 Cr | ₹3 Cr | ₹15 Cr | ₹8 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
| ₹1049 Cr | ₹610 Cr | ₹521 Cr | ₹403 Cr | ₹274 Cr | ₹272 Cr | ₹217 Cr | ₹137 Cr |
| ₹1621 Cr | ₹1076 Cr | ₹941 Cr | ₹575 Cr | ₹392 Cr | ₹355 Cr | ₹293 Cr | ₹201 Cr |
| ₹61 Cr | ₹117 Cr | ₹71 Cr | ₹66 Cr | ₹24 Cr | ₹6 Cr | ₹15 Cr | ₹9 Cr |
| ₹768 Cr | ₹450 Cr | ₹362 Cr | ₹255 Cr | ₹174 Cr | ₹159 Cr | ₹142 Cr | ₹83 Cr |
| — | — | — | — | — | — | — | — |
| ₹298 Cr | ₹166 Cr | ₹143 Cr | ₹131 Cr | ₹117 Cr | ₹105 Cr | ₹96 Cr | ₹57 Cr |
| ₹105 Cr | ₹73 Cr | ₹59 Cr | ₹47 Cr | ₹36 Cr | ₹27 Cr | ₹19 Cr | ₹9 Cr |
| ₹193 Cr | ₹93 Cr | ₹84 Cr | ₹83 Cr | ₹81 Cr | ₹78 Cr | ₹77 Cr | ₹48 Cr |
| ₹30 Cr | ₹9 Cr | ₹0 | ₹0 | ₹0 | ₹4 Cr | ₹2 Cr | ₹0 |
| ₹56 Cr | ₹37 Cr | ₹31 Cr | ₹21 Cr | ₹21 Cr | ₹12 Cr | ₹5 Cr | ₹9 Cr |
| ₹56 Cr | ₹37 Cr | ₹31 Cr | ₹21 Cr | ₹21 Cr | ₹12 Cr | ₹5 Cr | ₹9 Cr |
| ₹35 Cr | ₹11 Cr | ₹8 Cr | ₹5 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| ₹17 Cr | ₹12 L | ₹18 L | ₹23 L | ₹2 L | ₹0 | ₹0 | ₹0 |
| ₹332 Cr | ₹151 Cr | ₹124 Cr | ₹111 Cr | ₹106 Cr | ₹97 Cr | ₹87 Cr | ₹59 Cr |
| — | — | — | — | — | — | — | — |
| ₹857 Cr | ₹564 Cr | ₹423 Cr | ₹230 Cr | ₹165 Cr | ₹150 Cr | ₹115 Cr | ₹90 Cr |
| ₹182 Cr | ₹200 Cr | ₹185 Cr | ₹113 Cr | ₹61 Cr | ₹48 Cr | ₹35 Cr | ₹28 Cr |
| ₹60 Cr | ₹42 Cr | ₹127 Cr | ₹29 Cr | ₹14 Cr | ₹4 Cr | ₹2 Cr | ₹91 L |
| ₹19 Cr | ₹18 Cr | ₹12 Cr | ₹19 Cr | ₹12 Cr | ₹11 Cr | ₹8 Cr | ₹8 Cr |
| ₹171 Cr | ₹101 Cr | ₹69 Cr | ₹73 Cr | ₹35 Cr | ₹44 Cr | ₹46 Cr | ₹15 Cr |
| ₹1289 Cr | ₹926 Cr | ₹817 Cr | ₹464 Cr | ₹286 Cr | ₹257 Cr | ₹206 Cr | ₹142 Cr |
| ₹240 Cr | ₹315 Cr | ₹296 Cr | ₹61 Cr | ₹12 Cr | -₹15 Cr | -₹11 Cr | ₹5 Cr |
| ₹1621 Cr | ₹1076 Cr | ₹941 Cr | ₹575 Cr | ₹392 Cr | ₹355 Cr | ₹293 Cr | ₹201 Cr |
| ₹17 | ₹15 | ₹13 | ₹7 | ₹4 | ₹1,210 | ₹1,028 | ₹800 |
| ₹17 | ₹15 | ₹13 | ₹7 | ₹4 | ₹3 | ₹3 | ₹2 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|
| ₹75 Cr | ₹60 Cr | ₹87 Cr | ₹66 Cr | ₹36 Cr | ₹15 Cr | ₹20 Cr | ₹19 Cr |
| ₹62 Cr | ₹33 Cr | ₹22 Cr | ₹17 Cr | ₹11 Cr | ₹10 Cr | ₹6 Cr | ₹5 Cr |
| -₹233 Cr | -₹202 Cr | -₹234 Cr | -₹128 Cr | -₹37 Cr | -₹19 Cr | -₹45 Cr | -₹39 Cr |
| -₹96 Cr | -₹109 Cr | -₹124 Cr | -₹45 Cr | ₹11 Cr | ₹6 Cr | -₹19 Cr | -₹16 Cr |
| -₹111 Cr | -₹112 Cr | -₹150 Cr | -₹56 Cr | ₹5 Cr | ₹2 Cr | -₹25 Cr | -₹20 Cr |
| -₹146 Cr | -₹35 Cr | -₹48 Cr | -₹3 Cr | -₹11 Cr | -₹14 Cr | -₹28 Cr | -₹23 Cr |
| ₹267 Cr | ₹56 Cr | ₹266 Cr | ₹75 Cr | ₹15 Cr | ₹13 Cr | ₹54 Cr | ₹34 Cr |
| ₹10 Cr | -₹91 Cr | ₹68 Cr | ₹15 Cr | ₹8 Cr | ₹2 Cr | ₹74 L | -₹9 Cr |
| ₹3 Cr | ₹94 Cr | ₹27 Cr | ₹12 Cr | ₹3 Cr | ₹1 Cr | ₹91 L | ₹10 Cr |
| ₹13 Cr | ₹3 Cr | ₹94 Cr | ₹27 Cr | ₹12 Cr | ₹3 Cr | ₹2 Cr | ₹91 L |
Fundamental Ratios
Consolidated
Standalone

No results found
Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 5 out of 9 oscillators
RSI
40.33Sell
STOCH %K
13.89Buy
MACD Level(12,26)
-0.24Sell
Ultimate Oscillator
44.79Sell
Aroon Oscillator
-54.00Sell
BOP
-0.55Sell
CCI
-57.73Neutral
Williams %R
-86.11Buy
Momentum
0.54Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 1
Bearish signals: 8 out of 9 moving averages
EMA 9
25.69Sell
SMA 9
26.14Sell
EMA 21
25.95Sell
SMA 21
25.60Sell
EMA 50
26.16Sell
SMA 50
26.78Sell
EMA 200
25.54Sell
SMA 200
24.41Buy
WMA 20
25.92Sell
Pivot
Pivot
Classic
Resistance 5
29.74
Resistance 4
28.59
Resistance 3
27.44
Resistance 2
26.29
Resistance 1
25.72
Pivot
25.14
Support 1
24.57
Support 2
23.99
Support 3
22.84
Support 4
21.69
Support 5
20.54
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 73.33% | 73.33% | 73.33% | 73.33% | 73.33% | 73.33% |
| 1.70% | 1.73% | 1.70% | 1.70% | 1.70% | 2.08% |
| 0.20% | 0.00% | 0.00% | 0.17% | 1.66% | 1.87% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 24.77% | 24.94% | 24.97% | 24.80% | 23.31% | 22.72% |
Bulk & block deals
Name
Graviton Research Capital Llp
Dipan Mehta Commodities Private Limited
Yuga Stocks And Commodities Private Limited .
Graviton Research Capital Llp
Dipan Mehta Commodities Private Limited
Hrti Private Limited
Hrti Private Limited
Nk Securities Research Private Limited
Nk Securities Research Private Limited
Yuga Stocks And Commodities Private Limited .
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 16 Jul 2024 | Purchase | 15.62 Cr | ₹52.96 | 29.50 L | Bulk | 0.983405 | NSE |
| 16 Jul 2024 | Purchase | 9.59 Cr | ₹54.24 | 17.68 L | Bulk | 0.589496 | NSE |
| 16 Jul 2024 | Sell | 10.73 Cr | ₹54.06 | 19.85 L | Bulk | 0.661665 | NSE |
| 16 Jul 2024 | Sell | 15.65 Cr | ₹53.04 | 29.50 L | Bulk | 0.983405 | NSE |
| 16 Jul 2024 | Sell | 9 Cr | ₹53.93 | 16.69 L | Bulk | 0.556328 | NSE |
| 16 Jul 2024 | Sell | 23.51 Cr | ₹53.16 | 44.23 L | Bulk | 1.474379 | NSE |
| 16 Jul 2024 | Purchase | 23.94 Cr | ₹53.14 | 45.06 L | Bulk | 1.501883 | NSE |
| 16 Jul 2024 | Purchase | 12.90 Cr | ₹53.59 | 24.07 L | Bulk | 0.802462 | NSE |
| 16 Jul 2024 | Sell | 12.91 Cr | ₹53.62 | 24.07 L | Bulk | 0.802462 | NSE |
| 16 Jul 2024 | Purchase | 11.13 Cr | ₹56.06 | 19.85 L | Bulk | 0.661665 | NSE |
Insider trading & SAST
Client name
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|
Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
Mukka Proteins is engaged in the business of manufacturing of Fish Protein (i.e. fish meal, fish oil and fish soluble paste) and Insect Protein (i.e. insect meal and insect oil),
Corporate Actions
Date
Type
Details
Company details
Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Mukka Proteins Share Price
24.71+0.00 (-1.79%)
+0.16% past 1 Year
News
1 of 20
ResultMUKKA7 Nov 2026
Mukka Proteins reported Q2 revenue of approximately Rs 509 crores, up 108.1% year on year from Rs 245 crores. EBITDA increased 104.0% YoY to Rs 42.27 crores from Rs 20.72 crores, while EBITDA margin declined to 8.31% from 8.47%. PAT rose to Rs 15.99 crores from Rs 5.88 crores, representing 172% YoY growth. The results indicate substantial expansion in operating earnings and profitability, although the marginal decline in EBITDA margin reflects lower operating efficiency on a percentage basis. No QoQ comparison, analyst consensus, or market reaction was provided in the available information.
Mukka Proteins Reports Strong Second Quarter Revenue and Net Profit Growth
ResultMUKKA7 Nov 2026
Mukka Proteins reported consolidated Q2 FY27 revenue of Rs 508.87 crores, up 108.06% year on year from Rs 244.58 crores and 3.93% quarter on quarter from Rs 489.65 crores. Consolidated net profit stood at Rs 17.73 crores, rising 157.51% year on year from Rs 6.88 crores, while declining 4.87% quarter on quarter from Rs 18.63 crores.
EBITDA increased 90.73% year on year to Rs 50.12 crores. The EBITDA margin moderated to approximately 9.85% from 10.74% in the year-earlier quarter, indicating pressure despite strong revenue growth. Net profit margin improved year on year to approximately 3.48% from 2.81%.
The results reflect substantial year-on-year expansion in consolidated revenue and profitability, although sequential profit declined and operating margins softened. No street consensus or management guidance was provided in the available information.
Mukka Proteins Oman Subsidiary Begins Commercial Production Operations
Stock NewsMUKKA9 Oct 2026
Mukka Proteins announced that its overseas subsidiary has commenced commercial production in Oman. The development marks the operational start of the subsidiary and strengthens the company’s manufacturing presence and market access in the Middle East.
The available information does not specify the facility’s production capacity, investment quantum, product volumes, or expected revenue contribution. Therefore, the immediate impact on earnings, leverage, and market share cannot be quantified. Commercial production could support future international growth and improve regional supply capabilities, subject to utilisation levels and demand.
The company’s Oman expansion is linked to its fish protein products business, including fish meal, fish oil, and soluble paste used in aqua, poultry, and pet feed. No verified stock price reaction for the announcement day was available in the provided information.
Mukka Proteins Receives USDA NOP Inputs Attestation For Organic Fertilizer
Stock NewsMUKKA6 Oct 2026
Mukka Proteins has received USDA NOP inputs attestation for its Eco Sphere Organic Fertilizer from Ecocert S.A.S. The certification supports the product’s eligibility and marketability in organic farming markets, including the US. The development may help Mukka Proteins expand its presence in sustainable agricultural inputs and access additional organic farming customers. The announcement does not disclose any order value, revenue contribution, production capacity, investment amount, or earnings guidance. No specific stock price impact is available in the provided information.
Mukka Proteins To Hold Analyst And Investor Meeting On September 25
Stock NewsMUKKA22 Sept 2026
Mukka Proteins plans to hold a meeting with analysts and investors on September 25. The announcement relates to investor engagement and does not disclose any merger, acquisition, stake sale, buyback, dividend, rights issue, capital expenditure, management change, regulatory order, financial results, or specific earnings guidance. No quantum, operational target, leverage impact, or market share implication was provided. The meeting may offer additional information on the company’s business and financial outlook, but its impact cannot be assessed from the available details.
Mukka Proteins gains EU input certification for Eco Sphere organic fertilizer
Stock NewsMUKKA4 Sept 2026
Mukka Proteins has received EU Input Certification from ECOCERT for its Eco Sphere branded organic fertilizer, with the certification remaining valid until March 31, 2028. This development formally recognises Eco Sphere as compliant with European Union input standards applicable for use in organic farming systems, subject to ongoing adherence to specified quality and process norms over the certification period. The extended validity horizon provides Mukka Proteins with multi-year regulatory visibility for this product line, which can support long-term customer contracts and market development initiatives targeting organic agriculture segments.
The ECOCERT EU Input Certification is relevant for positioning Eco Sphere organic fertilizer in international markets where buyers and regulators increasingly demand traceability and third-party validated sustainability credentials. For Mukka Proteins, this certification potentially enhances product acceptance among distributors and institutional buyers focused on organic and sustainable farming inputs, and may improve pricing power relative to uncertified offerings. Over time, wider adoption of Eco Sphere in certified organic farming ecosystems could contribute to revenue diversification beyond the companys existing core operations, with incremental upside to margins if the product can command premium pricing. However, the immediate financial impact cannot be quantified from the available information, as specific data on current sales contribution, capacity, pricing or planned scale-up for Eco Sphere has not been disclosed. There is also no data yet on stock price reaction or changes in market share following the certification announcement. Overall, the certification strengthens Mukka Proteins regulatory and quality positioning in the organic fertilizer segment and provides a structured framework for tapping demand from EU-compliant organic farming customers over the next two years.
Mukka Proteins expands Bengaluru wet waste conversion into insect-based products
Stock NewsMUKKA1 Sept 2026
Mukka Proteins has highlighted its ongoing efforts to expand circular bio-economy initiatives by increasing the conversion of wet waste in Bengaluru into high-value insect-derived products. The company is focusing on transforming locally generated organic wet waste into insect protein, insect oil, compost, and humic acid, thereby creating a sustainable value chain around waste management and resource recovery. This initiative aligns with broader environmental and sustainability trends, aiming to reduce landfill burden, lower greenhouse gas emissions associated with unmanaged organic waste, and support regenerative agriculture through nutrient-rich compost and soil conditioners.
From a business perspective, the development reinforces Mukka Proteins’ positioning in alternative protein and allied products, with potential long-term benefits for diversification of revenue streams and margin profile, as insect protein and oil can be used in animal feed, aquaculture, and other industrial applications. The focus on Bengaluru suggests a scalable urban-centric model where increasing volumes of municipal and commercial wet waste could be converted into commercial products, potentially enhancing capacity utilisation of processing facilities and supporting future growth in volumes. While no specific financial metrics, capacity additions, or investment outlays are disclosed in the available context, the initiative indicates continued strategic emphasis on sustainable processing technologies and circular bio-economy solutions. In the absence of quantified guidance on earnings impact, leverage, or immediate changes in market share, the news is best interpreted as a qualitative positive for the company’s environmental credentials and long-term business positioning, without clear evidence of near-term balance sheet or profit and loss implications.
Mukka Proteins plans 1,000 tpd wet-waste processing to scale bio-economy unit
Stock NewsMUKKA1 Sept 2026
Mukka Proteins, listed on Indian exchanges under the symbol MUKKA, has outlined an expansion plan in its bio-economy business centered on wet-waste processing. The company is targeting a processing capacity of 1,000 tonnes per day (tpd) of wet waste by December 2027. This initiative suggests a strategic focus on converting wet waste into value-added bio-economy products, potentially including animal feed ingredients, biofuels, or other sustainable outputs, although specific product lines are not detailed in the available context. The planned capacity indicates a significant scale-up from current operations and aligns with broader industry trends toward circular economy practices and resource recovery.
From a corporate strategy perspective, the move appears to be a forward-looking capacity expansion that could enhance Mukka Proteins' revenue visibility over the medium term by tapping into growing demand for sustainable bio-based inputs. Larger wet-waste processing capability may help the company secure long-term feedstock arrangements, improve operating efficiencies, and diversify its earnings profile beyond traditional product segments. It could also support margin resilience if the company is able to command better realisations from higher value bio-economy products and leverage economies of scale. The timeline to December 2027 suggests that the impact on reported financials will be gradual, with investments and implementation likely to be phased over multiple years. There is no explicit information on capex size, funding mix, regulatory approvals, or current capacity, so these aspects cannot be quantified. The news does not mention any immediate change in leverage, capital structure, or a concurrent corporate action such as M&A, buyback, or dividend. Similarly, there is no verifiable data on same-day stock price reaction or trading volumes around the announcement. Overall, the development is a company-specific operational expansion in the bio-economy segment rather than a broader sector or macro event.
Mukka Proteins gets nod to make strategic investment in Aqua Marine
Stock NewsMUKKA15 Jun 2026
The Board of Directors of the Company at their meeting held on June 12, 2026, have approved the same
Mukka Proteins to acquire 51 percent stake in Aqua Marine via investment
Stock NewsMUKKA12 Jun 2026
Mukka Proteins has received approval to invest up to Rs 15 crores in Aqua Marine in order to acquire a 51 percent ownership stake. This transaction structure indicates a controlling investment, allowing Mukka Proteins to hold majority ownership and gain decision-making control in Aqua Marine. The proposed investment quantum of up to Rs 15 crores suggests a targeted allocation of capital toward expanding Mukka Proteins’ presence in the allied aquaculture or marine-related value chain, though specific deployment details have not been disclosed in the provided context.
Gaining a 51 percent stake typically enables consolidation of the target entity’s financials, which can potentially augment Mukka Proteins’ consolidated revenues and operating scale over time, depending on Aqua Marine’s existing operations and growth trajectory. The move may support vertical or horizontal integration within the broader protein, feed, or marine products ecosystem, and could help Mukka Proteins deepen its product portfolio, strengthen sourcing capabilities, or access new customers and geographies. The approval for this investment also reflects a willingness by Mukka Proteins’ management to deploy balance sheet resources for strategic inorganic growth rather than purely organic capacity additions. However, the immediate impact on leverage, margins, or earnings visibility cannot be quantified from the available information, as details on valuation metrics, funding mix, timelines for completion, and Aqua Marine’s financial performance are not specified in the context.
From a market perspective, such a majority-stake acquisition proposal is typically viewed as a strategic corporate development. Near-term stock price reaction will depend on investor perception of Aqua Marine’s business strength, synergy potential, and the return profile of the Rs 15 crores capital outlay. In the absence of additional disclosures on profitability, integration plans, or regulatory timelines, the development can primarily be interpreted as an expansion-focused corporate action aimed at enhancing Mukka Proteins’ strategic positioning in its core and adjacent markets.
Mukka Proteins informs about press release
Stock NewsMUKKA16 May 2026
NULL
Mukka Proteins Q4 EBITDA rises with improved operating margin performance YoY
ResultMUKKA15 May 2026
Mukka Proteins has reported a year-on-year improvement in operating performance for the fourth quarter, led by higher EBITDA and an expansion in operating margin. Q4 EBITDA came in at Rs 33.90 crores compared with Rs 29.10 crores in the corresponding quarter last year, indicating a meaningful increase in operating profit on an absolute basis. This rise in EBITDA suggests better operating leverage, improved cost management, firmer realisations, or a combination of these factors within the company’s core operations.
The company’s Q4 EBITDA margin improved to 8.9 percent from 7.6 percent in the same period a year ago, reflecting a 130 basis points expansion in profitability at the operating level. A higher margin indicates that Mukka Proteins was able to convert a larger portion of its revenue into operating profit compared to the previous year, which is typically viewed as a positive sign of operational efficiency or a more favourable product mix. While detailed revenue, PAT and sequential (QoQ) performance metrics are not provided in the available context, the combination of higher EBITDA and margin expansion underlines a stronger operating profile for the quarter on a year-on-year basis.
No information is available in the provided context regarding market expectations, broker estimates, or immediate stock price reaction, and there is also no disclosed management commentary or forward-looking guidance. As such, the analysis is confined to the reported Q4 operating performance, which currently points to improving profitability trends at Mukka Proteins on a year-on-year comparison.
Mukka Proteins reports Profit after tax of 18.91 Crores, in the March 2026 quarter
ResultMUKKA15 May 2026
NULL
Mukka Proteins Q4 profit rises sharply year-on-year on stable revenue base
ResultMUKKA15 May 2026
Mukka Proteins reported its Q4 consolidated results with a healthy improvement in profitability on a flat revenue base. Q4 consolidated net profit came in at Rs 20.60 crores, compared with Rs 13.60 crores in the same quarter last year, indicating a strong year-on-year rise in earnings. This sharp increase in profit suggests better cost management, improved product mix, or operational efficiencies despite no topline expansion over the comparable period.
On the revenue front, Mukka Proteins posted Q4 revenue of Rs 380.00 crores, exactly in line with Rs 380.00 crores recorded in the year-ago quarter. The flat revenue trajectory indicates that the key driver of bottom-line growth for the quarter was margin expansion rather than sales growth. While detailed margin metrics such as EBITDA margin and net margin are not provided in the available information, the divergence between stable revenue and higher net profit points to an improvement in underlying profitability.
There is no information in the current context on quarter-on-quarter performance, detailed cost trends, segment-wise performance, or any management guidance. Consensus or street expectations for the quarter are also not mentioned, so the degree of outperformance or underperformance versus forecasts cannot be precisely gauged. Additionally, the immediate stock price reaction and market commentary are not available in the provided data. Overall, based solely on the reported figures, Mukka Proteins has delivered a quarter marked by strong year-on-year earnings growth on a steady revenue base, reflecting enhanced efficiency and better profit conversion from a similar scale of operations.
Mukka Proteins informs about analyst meet
Stock NewsMUKKA6 Mar 2026
NULL
Mukka Proteins informs about analyst meet
Stock NewsMUKKA2 Mar 2026
NULL
Mukka Proteins completes acquisition of 100% stake in Ento Proteins
Stock NewsMUKKA24 Feb 2026
The company has acquired 1,000 equity shares of face value of Rs 100 each of EPPL
Mukka Proteins Q3 EBITDA Rises YoY to Rs 45.50 Crores but Margin Contracts to 6.96%
ResultMUKKA12 Feb 2026
Mukka Proteins reported Q3 **EBITDA** of **Rs 45.50 crores**, up from **Rs 41.30 crores** YoY, though **EBITDA margin** declined to **6.96%** from **13.62%** YoY. Revenue stood at **Rs 170.77 crores**, reflecting a **1% YoY decline** and **55.25% QoQ decrease** from Rs 381.57 crores. Operating profit was **Rs 13.60 crores**, down **6.01% QoQ** but up **23.86% YoY**. Net profit was **Rs 5.88 crores**, up **286.84% QoQ** from Rs 1.52 crores but down **182.69%** from prior year per some reports, with other data showing **Rs 1.52 crores** down **64.07% YoY** and **88.82% QoQ**. PBDT at **Rs 4.03 crores** fell **54.82% QoQ** but grew **18.18% YoY**; Profit Before Tax at **Rs 2.36 crores** declined **88.26% QoQ** and **57.48% YoY**. Margin contraction and revenue drop highlight pressures amid elevated interest costs of **Rs 12.82 crores**. No consensus expectations or management guidance provided in available data.
Mukka Proteins Q3 FY26 Results: Net Profit Declines YoY Amid Revenue Growth
ResultMUKKA12 Feb 2026
Mukka Proteins Limited reported Q3 FY26 consolidated net profit of Rs 23.80 crores against Rs 26.30 crores in Q3 FY25, representing a 9.50% year-on-year decline. Revenue for the quarter stood at Rs 650.00 crores versus Rs 300.00 crores in the corresponding prior year period, reflecting 116.67% YoY growth.
Despite robust top-line expansion, profitability metrics deteriorated on a sequential basis. Operating profit declined 6.01% quarter-on-quarter to Rs 13.60 crores, though it improved 23.86% year-on-year. Profit Before Tax fell sharply by 88.26% QoQ to Rs 2.36 crores but registered 18.18% YoY growth in PBDT at Rs 4.03 crores. Net margins compressed, with the company reporting a 4.35% net margin against the food industry average of 17.61%.
The company has reported negative results for seven consecutive quarters, with persistent debt servicing pressures evidenced by a Debt to EBITDA ratio of 5.26 times and quarterly interest expenses of Rs 12.82 crores—the highest in recent quarters. Return on Capital Employed stands at 9.16%, considered low within the FMCG sector. Operating profit growth of 50.86% annually over the medium term contrasts with modest net sales growth of 8.60% per annum over five years, indicating operational efficiency improvements offset by margin pressures and financial leverage concerns.
Stock performance has been notably weak, with the company hitting all-time lows and posting a one-year negative return of 33%, significantly underperforming the Sensex's ten-year gain of 239.97%.
Despite robust top-line expansion, profitability metrics deteriorated on a sequential basis. Operating profit declined 6.01% quarter-on-quarter to Rs 13.60 crores, though it improved 23.86% year-on-year. Profit Before Tax fell sharply by 88.26% QoQ to Rs 2.36 crores but registered 18.18% YoY growth in PBDT at Rs 4.03 crores. Net margins compressed, with the company reporting a 4.35% net margin against the food industry average of 17.61%.
The company has reported negative results for seven consecutive quarters, with persistent debt servicing pressures evidenced by a Debt to EBITDA ratio of 5.26 times and quarterly interest expenses of Rs 12.82 crores—the highest in recent quarters. Return on Capital Employed stands at 9.16%, considered low within the FMCG sector. Operating profit growth of 50.86% annually over the medium term contrasts with modest net sales growth of 8.60% per annum over five years, indicating operational efficiency improvements offset by margin pressures and financial leverage concerns.
Stock performance has been notably weak, with the company hitting all-time lows and posting a one-year negative return of 33%, significantly underperforming the Sensex's ten-year gain of 239.97%.
Mukka Proteins reports Profit after tax of 17.26 Crores, in the December 2025 quarter
ResultMUKKA12 Feb 2026
NULL

